Hims & Hers up 18% amid optimism for compounders with Makary FDA pick

seekingalpha11-26

Noam Galai Hims & Hers Health (NYSE:HIMS) is up 18% Monday as the Street appears to believe that President-Elect Donald Trump's nomination of Marty Makary for U.S. FDA Commissioner will be positive ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486053571?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1081805356/image_1081805356.jpg","is_english":true,"pubTime":"2024-11-26 01:46","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2486053571","market":"sh","top_or_hot":-1,"title":"Hims & Hers up 18% amid optimism for compounders with Makary FDA pick","media":"seekingalpha","content":"<div>\n<p>Noam Galai Hims & Hers Health (NYSE:HIMS) is up 18% Monday as the Street appears to believe that President-Elect Donald Trump's nomination of Marty Makary for U.S. FDA Commissioner will be positive ...</p>\n\n<a href=\"https://seekingalpha.com/news/4330979-hims-hers-up-18-optimism-compounders-makary-fda-pick\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers up 18% amid optimism for compounders with Makary FDA pick</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers up 18% amid optimism for compounders with Makary FDA pick\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 01:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4330979-hims-hers-up-18-optimism-compounders-makary-fda-pick><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Noam Galai Hims & Hers Health (NYSE:HIMS) is up 18% Monday as the Street appears to believe that President-Elect Donald Trump's nomination of Marty Makary for U.S. FDA Commissioner will be positive ...</p>\n\n<a href=\"https://seekingalpha.com/news/4330979-hims-hers-up-18-optimism-compounders-makary-fda-pick\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4330979-hims-hers-up-18-optimism-compounders-makary-fda-pick","article_id":"2486053571","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1081805356/image_1081805356.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486053571","pubTimestamp":1732556773,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Noam Galai Hims & Hers Health  is up 18% Monday as the Street appears to believe that President-Elect Donald Trump's nomination of Marty Makary for U.S. FDA Commissioner will be positive for drug compounders and companies that sell their products. Besides being a pancreatic surgeon at Johns Hopkins University, Makary is the chief medical officer for Sesame, a privately held telehealth provider whose website states the company offers compounded semaglutide, the active ingredient in Novo Nordisk's  blockbuster weight-loss med Wegovy.  Hunterbrook Media, part of Hunterbrook Capital, which had previously put out a short report on Hims & Hers Health, reversed course Monday and is now long on the stock. Hunterbrook noted that the company could have a \"key ally\" in Makary. Both Novo and Eli Lilly , which markets the rival obesity drug Zepbound , have filed lawsuits against compounders.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务"},"translate_title":"Hims&Hers股价上涨18%，对Makary FDA选择的复合机持乐观态度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"Noam Galai Hims & Hers Health (NYSE:HIMS) is up 18% Monday as the Street appears to believe that President-Elect Donald Trump's nomination of Marty Makary for U.S. FDA Commissioner will be positive for drug compounders and companies that sell their products. Besides being a pancreatic surgeon at Johns Hopkins University, Makary is the chief medical officer for Sesame, a privately held telehealth provider whose website states the company offers compounded semaglutide, the active ingredient in Novo Nordisk's (NVO) blockbuster weight-loss med Wegovy.  Hunterbrook Media, part of Hunterbrook Capital, which had previously put out a short report on Hims & Hers Health, reversed course Monday and is now long on the stock. Hunterbrook noted that the company could have a \"key ally\" in Makary. Both Novo and Eli Lilly (LLY), which markets the rival obesity drug Zepbound (tirzepatide), have filed lawsuits against compounders.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486053571"}